CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC

Bookmark and Share
Published: 19 Feb 2020
Views: 853
Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA

Dr Anis Hamid speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the CHAARTED trial.

After an overview of the history of the trial, he explains how this study provided a more personalised direction based on the CHAARTED trial outcomes.